Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker ​C

The Italian pharma company grows its presence in the U.S. market and strengthens its global leadersh

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260709-1484347/1484347_cprx6.p

HC Wainwright & Co. analyst Andrew S. Fein downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.79 per share which beat the

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly sales of $149.390 million which beat the a

Citigroup analyst Samantha Semenkow downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) from Buy to

Major M&A deals this week include: Gamestop's proposal to acquire eBay, Long Lake buys Ameri

Catalyst Pharmaceuticals stock rose after Angelini Pharma agreed to acquire the rare disease drugmak

Stephens & Co. analyst Sudan Loganathan downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) fro

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved th

https://www.bloomberg.com/news/articles/2026-04-27/italy-s-angelini-said-to-explore-acquisition-of-c

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001369568/000119312526114306/d111324d8k.htm

Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceuti

Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy a

Catalyst Pharmaceuticals (NASDAQ:CPRX) sees FY2026 sales of $615.000 million-$645.000 million vs $61

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the

Jim Cramer recommended holding Texas Instruments (TXN) on CNBC's Mad Money, supported by an anal

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a